For the roughly 1 to 2 percent of pancreatic-cancer patients whose tumors carry a specific genetic glitch called KRAS G12C, treatment options after chemotherapy fails have been essentially nonexistent.

The overall survival rate for people who got daraxonrasib was 13.2 months, nearly double the 6.7 months people survived on standard chemotherapy alone.

Pill users lived an average of 13.2 months versus 6.7 months for those undergoing chemotherapy

For roughly four decades, oncologists had a grim shorthand for the most common genetic driver of pancreatic cancer: undruggable. The KRAS protein, mutated in about 90 percent of pancreatic tumors, resisted every small molecule researchers threw at it.

Researchers at the University of Oslo and Oslo University Hospital have developed a promising new immunotherapy targeting the CTNNB1 gene mutation associated with various aggressive cancers such as lung and prostate cancer. This approach has effectively ...

Population-based pathogenic variant testing identified breast cancer susceptibility gene carriers who would often be missed by clinical risk models, even when polygenic risk scores were added. In the WISDOM Study analysis,

The new breast cancer screening guidelines are creating mixed signals on when to start screening. Medical News Today spoke to 2 experts to explain the latest changes.

Lung cancer is the most common and deadly form of cancer worldwide. It is increasingly understood to be a complex genetic disease with different mutations that vary according to factors such as smoking and ethnicity.